DOCSLIB.ORG

Havemeyer Foundation Monograph Series 9

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Havemeyer Foundation Monograph Series 9 H av on emeyer Foundati Havemeyer Foundation Monograph Series No. 9 Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE: DEFINING THE SYNDROME 30th September – 3rd October 2002 Boston, USA Editors: A. Hoffman, N. E. Robinson and J. F. Wade H av on emeyer Foundati Havemeyer Foundation Monograph Series No. 9 Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE: DEFINING THE SYNDROME 30th September – 3rd October 2002 Boston, USA Editors: A. Hoffman, N. E. Robinson and J. F. Wade © 2003 by R & W Publications (Newmarket) Limited Suites 3 & 4, 8 Kings Court, Willie Snaith Road, Newmarket, Suffolk CB8 7SG, UK No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. Authorisation to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by R & W Publications (Newmarket) Limited for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of £0.02 per copy (no additional fee per page) is paid directly to CCC, 21 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. First published 2003 ISSN 1472-3158 Published by R & W Publications (Newmarket) Limited Printed in Great Britain by Quality Print Services (Anglia) Limited Havemeyer Foundation Monograph Series No. 9 CONTENTS EDITORS’ FOREWORD .....................................................................................................................Page v SESSION 1: CLINICAL EVIDENCE Inflammatory airway disease: a clinician’s view from North America B. R. Rush ..........................................................................................................................................Page 3 Inflammatory airway disease: European clinician’s perspective P. M. Dixon, B. C. McGorum and R. S. Pirie ....................................................................................Page 7 Inflammatory airway disease: effect of athletic discipline M. Mazan and A. Hoffman..................................................................................................................Page 9 Mucus, cough, airway obstruction and inflammation N. E. Robinson, C. Berney, H. DeFeijter-Rupp, A. M. Jefcoat, C. Cornelisse, V. Gerber and F. J. Derksen ..............................................................................................................................Page 13 Relationship between coughing and airway inflammation in young racehorses D. R. Hodgson, R. M. Christley, J. L. N. Wood, S. W. J. Reid and J. L. Hodgson ...........................Page 16 Poor performance: the trainer’s perspective (sport horse) C. Platz ............................................................................................................................................Page 19 The diagnostic approach to chronic cough in people A. J. Ghio ..........................................................................................................................................Page 23 SESSION 2: AETIOLOGY Aetiological agents: indoor environment and endotoxin B. C. McGorum and R. S. Pirie .......................................................................................................Page 27 Aetiological agents: outdoor environment and airways A. J. Ghio ........................................................................................................................................Page 29 Aetiological agents: allergy and related mediators J. P. Lavoie .......................................................................................................................................Page 31 Aetiological agents: viruses and inflammatory airway disease J. L. N. Wood, J. R. Newton, K. C. Smith and D. J. Marlin ............................................................Page 33 Natural history of equine influenza H. G. G. Townsend............................................................................................................................Page 37 Aetiological agents: bacteria J. R. Newton, J. L. N. Wood, K. C. Smith, D. J. Marlin and N. Chanter .........................................Page 40 Dysregulation of inflammation F. Bureau and P. Lekeux ...................................................................................................................Page 45 iii Inflammatory Airway Disease SESSION 3: DIAGNOSTIC MEASURES OF INFLAMMATION Significance of tracheal inflammation J. L. Hodgson ....................................................................................................................................Page 49 Significance of bronchoalveolar cytology in inflammatory airway disease of horses L. Viel ................................................................................................................................................Page 52 Cytology of inflammatory airway disease K. C. Smith, J. R. Newton, S. M. Gower, S. M. Cade, D. J. Marlin and C. M. Deaton ...................Page 55 Quantifying and characterising mucus in the airways V. Gerber, A. M. Jefcoat, J. A. Hotchkiss, M. King and N. E. Robinson..........................................Page 59 Breath condensate measures of airway inflammation D. J. Marlin, C. M. Deaton, J. R. Newton and K. C. Smith .............................................................Page 62 SESSION 4: FUNCTIONAL SIGNIFICANCE Lung function for beginners F. J. Derksen .....................................................................................................................................Page 69 Airway obstruction and hyper-reactivity in horses with signs of inflammatory airway disease A. Hoffman and M. Mazan................................................................................................................Page 71 Inflammatory airway disease and gas exchange G. Nyman ..........................................................................................................................................Page 75 Functional imaging of inflammatory airway disease D. Votion ...........................................................................................................................................Page 81 Inflammatory airway disease and clinical exercise testing L. Couëtil ..........................................................................................................................................Page 84 WORKSHOP SUMMARY...................................................................................................................Page 89 LIST OF PARTICIPANTS...................................................................................................................Page 92 AUTHOR INDEX ...............................................................................................................................Page 93 iv Havemeyer Foundation Monograph Series No. 9 EDITORS’ FOREWORD he nomenclature of equine non-infectious reversibility with drugs, ‘recurrent airway obstruction (RAO)’ was also deemed an airway disease is a source of puzzlement appropriate term. By exclusion, all other forms of to many. The terms ‘chronic obstructive T non-infectious airway disease are referred to as pulmonary disease (COPD)’, ‘inflammatory IAD, the topic of this workshop. airway disease (IAD)’, ‘chronic obstructive The Havemeyer Workshop series brings bronchitis (COB)’, ‘reactive airway disease’, together investigators from a range of disciplines ‘allergic bronchitis’, ‘heaves’, ‘broken wind’ and and locations to discuss topic of specific concern ‘small airway disease’ confuse vets and other to the horse industry. IAD is such a topic and we biomedical scientists. The plethora of terminology therefore invited clinicians, epidemiologists, reflects a poor understanding of the pathogenesis pathologists, microbiologists and physiologists to of equine airway disease and leads to confusion as share knowledge with each other. Several to the best way to treat and prevent airway disease. important questions must be addressed before we For years, ‘equine COPD’ was used to describe can provide solid answers about IAD. First, we any accumulation of neutrophils and mucus in the must decide what each of us means by the term airways in the absence of active infection, eg the IAD. Is the syndrome seen in young racehorses mature horse with severe heaves and the younger similar to that of the older ‘cougher without animal with reduced performance, increased airway heaves’? How important is infection? Does the neutrophils and mucus. However, the 2 conditions culture of organisms from the trachea mean that are very different and there is no evidence that the these organisms are causing functional changes in former is a consequence of the latter. A further the airways? Is inflammation regionalised in the source of confusion is the incongruous use of the lung? Does inflammation and mucus in the term in human and veterinary medicine. In human trachea indicate lower airway inflammation? medicine, COPD is a disease of aged smokers and What are the functional consequences of IAD and the term would not be used to describe a young the clinical consequences to the horse? Finally, athlete with a cough, increased
Load more

Recommended publications
  • USMLE – What's It
    Purpose of this handout Congratulations on making it to Year 2 of medical school! You are that much closer to having your Doctor of Medicine degree. If you want to PRACTICE medicine, however, you have to be licensed, and in order to be licensed you must first pass all four United States Medical Licensing Exams. This book is intended as a starting point in your preparation for getting past the first hurdle, Step 1. It contains study tips, suggestions, resources, and advice. Please remember, however, that no single approach to studying is right for everyone. USMLE – What is it for? In order to become a licensed physician in the United States, individuals must pass a series of examinations conducted by the National Board of Medical Examiners (NBME). These examinations are the United States Medical Licensing Examinations, or USMLE. Currently there are four separate exams which must be passed in order to be eligible for medical licensure: Step 1, usually taken after the completion of the second year of medical school; Step 2 Clinical Knowledge (CK), this is usually taken by December 31st of Year 4 Step 2 Clinical Skills (CS), this is usually be taken by December 31st of Year 4 Step 3, typically taken during the first (intern) year of post graduate training. Requirements other than passing all of the above mentioned steps for licensure in each state are set by each state’s medical licensing board. For example, each state board determines the maximum number of times that a person may take each Step exam and still remain eligible for licensure.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE
    H av on emeyer Foundati Havemeyer Foundation Monograph Series No. 9 Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE: DEFINING THE SYNDROME 30th September – 3rd October 2002 Boston, USA Editors: A. Hoffman, N. E. Robinson and J. F. Wade H av on emeyer Foundati Havemeyer Foundation Monograph Series No. 9 Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE: DEFINING THE SYNDROME 30th September – 3rd October 2002 Boston, USA Editors: A. Hoffman, N. E. Robinson and J. F. Wade © 2003 by R & W Publications (Newmarket) Limited Suites 3 & 4, 8 Kings Court, Willie Snaith Road, Newmarket, Suffolk CB8 7SG, UK No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. Authorisation to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by R & W Publications (Newmarket) Limited for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of £0.02 per copy (no additional fee per page) is paid directly to CCC, 21 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. First published 2003 ISSN 1472-3158 Published by R & W Publications (Newmarket) Limited Printed in Great Britain by Quality Print Services (Anglia) Limited Havemeyer Foundation Monograph Series No. 9 CONTENTS EDITORS’ FOREWORD .....................................................................................................................Page v SESSION 1: CLINICAL EVIDENCE Inflammatory airway disease: a clinician’s view from North America B.
    [Show full text]
  • Occupational Diseases
    OCCUPATIONAL DISEASES OCCUPATIONAL DISEASES ОДЕСЬКИЙ ДЕРЖАВНИЙ МЕДИЧНИЙ УНІВЕРСИТЕТ THE ODESSA STATE MEDICAL UNIVERSITY Áiáëiîòåêà ñòóäåíòà-ìåäèêà Medical Student’s Library Започатковано 1999 р. на честь 100-річчя Одеського державного медичного університету (1900–2000 рр.) Initiated in 1999 to mark the Centenary of the Odessa State Medical University (1900–2000) 1 OCCUPATIONAL DISEASES Recommended by the Central Methodical Committee for Higher Medical Education of the Ministry of Health of Ukraine as a manual for students of higher medical educational establishments of the IV level of accreditation using English Odessa The Odessa State Medical University 2009 BBC 54.1,7я73 UDC 616-057(075.8) Authors: O. M. Ignatyev, N. A. Matsegora, T. O. Yermolenko, T. P. Oparina, K. A. Yarmula, Yu. M. Vorokhta Reviewers: Professor G. A. Bondarenko, the head of the Department of Occupational Diseases and Radiation Medicine of the Donetzk Medical University named after M. Gorky, MD Professor I. F. Kostyuk, the head of the Department of Internal and Occupational Diseases of the Kharkiv State Medical University, MD This manual contains information about etiology, epidemiology, patho- genesis of occupational diseases, classifications, new methods of exami- nation, clinical forms and presentation, differential diagnosis, complica- tions and treatment. It includes the questions of prophylaxis, modern trends in treatment according to WHO adopted instructions, working capacity expert exam. The represented material is composed according to occupational dis- eases study programme and it is recommended for the students of higher medical educational establishments of the IV accreditation standard and doctors of various specialities. Рекомендовано Центральним методичним кабінетом з вищої медичної освіти МОЗ України як навчальний посібник для студентів вищих медичних навчальних закладів IV рівня акредитації, які опановують навчальну дисципліну англiйською мовою (Протокол № 4 від 24.12.2007 р.
    [Show full text]
  • Ep 1270000 A2
    Europäisches Patentamt *EP001270000A2* (19) European Patent Office Office européen des brevets (11) EP 1 270 000 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/00, A61K 31/353, 02.01.2003 Bulletin 2003/01 A61P 9/10 (21) Application number: 02254274.0 (22) Date of filing: 19.06.2002 (84) Designated Contracting States: • Bourassa, P.-A., AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Pfizer Global Research and Devel. MC NL PT SE TR Groton, Connecticut 06340 (US) Designated Extension States: • Lindsey, S., AL LT LV MK RO SI Pfizer Global Research and Developm. Groton, Connecticut 06340 (US) (30) Priority: 28.06.2001 US 301712 P 10.10.2001 US 328254 P (74) Representative: Sewell, Richard Charles et al UK Patent Department, (71) Applicant: Pfizer Products Inc. Pfizer Limited, Groton, Connecticut 06340 (US) Ramsgate Road Sandwich, Kent CT13 9NJ (GB) (72) Inventors: • Aiello, R. J., Pfizer Global Research and Develop. Groton, Connecticut 06340 (US) (54) Benzoic acid substituted benzopyrans for the treatment of atherosclerosis (57) A method of treating atherosclerosis in a mammal, including a human, comprising administering to said mam- mal an amount of the compound of the formula an enantiomer, or the pharmaceutically acceptable salt thereof; effective to treat atherosclerosis, wherein R1, R2 and R3 are as defined herein. EP 1 270 000 A2 Printed by Jouve, 75001 PARIS (FR) EP 1 270 000 A2 Description BACKGROUND OF THE INVENTION 5 [0001] This invention relates to the methods of treating atherosclerosis in a mammal, including a human, by admin- istering an amount of LTB4 antagonists, preferably substituted benzopyrans or a pharmaceutically acceptable salt thereof, effective in treating atherosclerosis.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Path Pulmonary Outline
    Pathology Pulmonary ATELECTASIS Neonatal Atelectasis ‐ The lungs of the neonate never inflate, a consequence of congenital defect, premature birth (insufficient surfactant), or other consequence, also called Patchy Atelectasis Adult or Acquired Atelectasis ‐ Collapse of Previously Inflated lung, creating areas of “airless parenchyma” ‐ Produces a well‐perfused but poorly‐ventilated region, predisposing for infection Decreased Volume ‐ Is a reversible disorder (except in the case of contraction) outside pleural space ‐ Resorption Atelectasis o Consequence of complete obstruction without impairment to blood flow Blockage o A decreased lung volume results in a mediastinal shift towards affected lung o Caused by a mucous plug associated with Asthma, Bronchitis, or Aspiration Pneumonia ‐ Compression Atelectasis o Consequence of partially or totally filled pleura with exudate (CHF), tumor, air (pneumothorax), blood (hemothorax), when air pressure threatens the function of lungs and great vessels (tension pneumothorax), or with an extra‐pulmonary mass compressing Something within lung parenchyma. pleural space compressing o Compressed lung tissue cannot expand and is therefore poorly ventilated. parenchyma o Compression pushes lung resulting in a mediastinal shift away from affected lung ‐ Contraction Atelectasis o Fibrotic changes prevent expansion, resulting in reduced lung volume and ventilation Fibrotic o This form is irreversible Changes are Irreversible PULMONARY EDEMA Pulmonary Edema is simply the accumulation of fluid in the alveolar
    [Show full text]
  • 数字 Accessory Bronchus 副気管支 Accessory Fissure 副葉間裂
    数字 accentuation 亢進 accessory 副の 数字 accessory bronchus 副気管支 accessory fissure 副葉間裂 10-ｙear survival 10年生存 accessory lobe 副肺葉 18F-fluorodeoxy glucose (FDG) 18F-フルオロデオキシグルコース accessory lung 副肺 2,3-diphosphoglycerate (2,3-DPG) 2,3ジフォスフォグリセレート accessory nasal sinus 副鼻腔 201TI (thallium-201) タリウム accessory trachea 副気管 5-fluorouracil（FU) 5-フルオロウラシル acclimation 順化 5-HT3 receptor antagonist 5-HT3レセプター拮抗薬 acclimation 馴化 5-hydroxytryptamine 5-ヒドロオキシトリプタミン acclimatization 気候順応 5-year survival 5年生存 acclimatization 順化 99mTc-macroaggregated albumin (99mTc-MAA) 99mTc標識大 acclimatization 馴化 凝集アルブミン accommodation 順応 accommodation 調節 accommodation to high altitude 高所順（適）応 A ACE polymorphism ACE遺伝子多型 acetone body アセトン体 abdomen 腹部 acetonuria アセトン尿［症］ abdominal 腹部［側］の acetylcholine(ACh) アセチルコリン abdominal breathing 腹式呼吸 acetylcholine receptor (AchR, AChR) アセチルコリン受容体（レセプ abdominal cavity 腹腔 ター） abdominal pressure 腹腔内圧 acetylcholinesterase (AchE, AChE) アセチルコリンエステラーゼ abdominal respiration 腹式呼吸 achalasia アカラシア abdominal wall reflex 腹壁反射 achalasia 弛緩不能症 abduction 外転 achalasia ［噴門］無弛緩［症］ aberrant 走性 achromatocyte (achromocyte) 無血色素［赤］血球 aberrant 迷入性 achromatocyte (achromocyte) 無へモグロビン［赤］血球 aberrant artery 迷入動脈 acid 酸 aberration 迷入 acid 酸性 ablation 剥離 acid base equilibrium 酸塩基平衡 abnormal breath sound(s) 異常呼吸音 acid fast 抗酸性の abortive 早産の acid fast bacillus 抗酸菌 abortive 頓挫性（型） acid-base 酸―塩基 abortive 不全型 acid-base balance 酸塩基平衡 abortive pneumonia 頓挫［性］肺炎 acid-base disturbance 酸塩基平衡異常 abrasion 剥離 acid-base equilibrium 酸塩基平衡 abscess 膿瘍 acid-base regulation 酸塩基調節 absolute
    [Show full text]
  • Keyword Associations
    Bare Minimum Keyword Associations USMLE & COMLEX Review Northwestern Medical Review [email protected] Northwestern Medical Review PO Box 22174 Lansing, Michigan 48909 www.northwesternmedicalreview.com Copyright © 2015 Northwestern Medical Review eBookit.com and Northwestern Medical Review Second Edition ISBN 978-0-9960-9340-1 All rights reserved. Written, published, and printed in the United States of America. No part of this book may be used, reproduced, or transmitted in any form or by any means, electronic or mechanical without written permission from its author or Northwestern Medical Review. All photos adapted from fotolia.com Northwestern Medical Review claims no rights to USMLE or COMLEX USMLE ® National Board of Medical Examiners COMLEX ® National Board of Osteopathic Medical Examiners This book is adapted from the first chapter of Primary Care for the USMLE and COMLEX by Northwestern Medical Review. The full book version is primarily intended to accompany online or live review courses from Northwestern Medical Review. How to use this book This book is adapted from the first chapter of Northwestern Medical Review’s Primary Care for the USMLE and COMLEX book. It contains exceptionally high-yield material found on board exams. The mini-chapters are divided into sections containing commonly tested concepts with keywords that should immediately come to mind while you’re taking your exam. In the back of the book are two additional sections: a Test Your Knowledge section containing questions and answers with explanations from our follow-along lecture workbooks and NMR Question Bank, and a Sample Mnemonics section containing examples of memorable mnemonics from our course material.
    [Show full text]
  • 1 Medical Student's Amnesia a Transient Selective Loss of Memory During an Exam That Prevents One from Remem
    Medical Student’s Amnesia A transient selective loss of memory during an exam that prevents one from remembering the eponymically-named diseases discovered by old, dead doctors. Addison’s Disease 1. Primary adrenocortical deficiency Addisonian Anemia 2. Pernicious anemia (antibodies to intrinsic factor or parietal cells → ↓IF → ↓Vit B12 → megaloblastic anemia) Albright’s Syndrome 3. Polyostotic fibrous dysplasia, precocious puberty, café au lait spots, short stature, young girls Alport’s Syndrome 4. Hereditary nephritis with nerve deafness Alzheimer’s 5. Progressive dementia Argyll-Robertson Pupil 6. Loss of light reflex constriction (contralateral or bilateral) 7. “Prostitute’s Eye” – accommodates but does not react 8. Pathognomonic for 3°Syphilis 9. Lesion pretectal region of superior colliculus Arnold-Chiari Malformation 10. Cerebellar tonsil herniation through foramen magnum = see thoracolumbar meningomyelocele Barrett’s 11. Columnar metaplasia of lower esophagus (↑ risk of adenocarcinoma)- constant gastroesophageal reflux Bartter’s Syndrome 12. Hyperreninemia Becker’s Muscular Dystrophy 13. Similar to Duchenne, but less severe (mutation, not a deficiency, in dystrophin protein) Bell’s Palsy 14. CNVII palsy (entire face; recall that UMN lesion only affects lower face) Berger’s Disease 15. IgA nephropathy causing hematuria in kids, usually following infection Bernard-Soulier Disease 16. Defect in platelet adhesion (abnormally large platelets & lack of platelet-surface glycoprotein) Berry Aneurysm 17. Circle of Willis (subarachnoid bleed) Anterior Communicating artery 18. Often associated with ADPKD Bowen’s Disease 19. Carcinoma in situ on shaft of penis (↑ risk of visceral ca) [compare w/ Queyrat] Brill-Zinsser Disease 20. Recurrences of rickettsia prowazaki up to 50 yrs later Briquet’s Syndrome 21.
    [Show full text]
  • WO 2009/114650 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 17 September 2009 (17.09.2009) WO 2009/114650 Al (51) International Patent Classification: (US). GOSWAMY, Amit [US/US]; 130 Knowles Drive, A61K 31/10 (2006.01) A61K 45/06 (2006.01) Suite A, Los Gatos, CA 95032 (US). A61K 31/195 (2006.01) A61P 29/00 (2006.01) (74) Agents: NOLAN, James S. @ et al.; Mintz Levin Cohn (21) International Application Number: Ferris Glovsky And Popeo, P.C , One Financial Center, PCT/US2009/036867 Boston, MA 021 11 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 11 March 2009 ( 11.03.2009) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/035,706 11 March 2008 ( 11.03.2008) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (71) Applicant (for all designated States except US): CHAK- NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SHU RESEARCH, INC. [US/US]; 130 Knowles Drive, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, Suite A, Los Gatos, CA 95032 (US).
    [Show full text]
  • In the Supreme Court of the United States ______
    No. 01-963 In the Supreme Court of the United States __________ NORFOLK & WESTERN RAILWAY COMPANY, Petitioner, v. FREEMAN AYERS, et al., Respondents. __________ On Writ of Certiorari to the Circuit Court of Kanawha County, West Virginia __________ BRIEF OF RESPONDENTS __________ SEAN DONAHUE RICHARD J. LAZARUS* WASHINGTON & LEE UNIV. GEORGETOWN UNIVERSITY SCHOOL OF LAW LAW CENTER LEXINGTON, VA 24450 600 NEW JERSEY AVE., N.W. WASHINGTON, D.C. 20001 JAMES H. RION, JR. (202) 662-9129 NESS MOTLEY 28 BRIDGESIDE BLVD JAMES A. MCKOWEN MT. PLEASANT, SC 29465 JAMES F. HUMPHREYS & ASSOCIATES, L.C. LAWRENCE M. MANN 500 VIRGINIA STREET, EAST ALPER & MANN, P.C. CHARLESTON, WV 25301 1667 K STREET, N.W. (304) 347-5050 WASHINGTON, D.C. 20006 * Counsel of Record Counsel for Respondents QUESTIONS PRESENTED The Federal Employer’s Liability Act (FELA), 45 U.S.C. § 51, provides that a railroad is liable in damages for injuries to railroad employees “resulting in whole or in part” from the railroad’s negligence. Respondents prevailed in a jury trial brought pursuant to FELA against petitioner based on injuries resulting from petitioner’s negligence in exposing respondents to asbestos at the workplace. The questions presented are: 1. Whether the trial judge properly instructed the jury that a plaintiff railroad employee who has a reasonable fear of cancer because he is suffering from a physical disease caused by the defendant railroad employer’s negligently exposing the plaintiff to asbestos is entitled to be compensated for that mental injury under FELA. 2. Whether the trial judge properly declined to instruct the jury in a FELA lawsuit to apportion damages between the defendant railroad employer and absent third parties where the plaintiff railroad employees were suffering from indivisible injuries caused by the railroad’s negligence.
    [Show full text]